News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stock Titan Balance sheet
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Plus Therapeutics (PSTV) has secured $15 million in financing and prefunded warrants, which analysts believe will accelerate clinical progress. While some analysts are bullish on the long-term potential, reflecting an updated fair value of $38, others express caution due to execution risks and valuation …
Plus Therapeutics has amended its bylaws to reflect a corporate name change to Cerenome, effective August 3, 2026. The company's Nasdaq trading symbol also switched to CNSY on the same date, though the CUSIP for the common stock remains unchanged. This news brief was …
Plus Therapeutics (PSTV) presented encouraging clinical data for its radiopharmaceutical REYOBIQ at the 2026 American Association of Neurological Surgeons Annual Scientific Meeting. The data from the Phase 1 ReSPECT-LM trial, which evaluates REYOBIQ for leptomeningeal metastases, showed a median overall survival of approximately 9 …
This article briefly reports on the discontinued operations of PLUS THERAPEUTICS, Inc. (NASDAQ: CNSY). The content is minimal, essentially just stating the fact and indicating that the market for CNSY is closed with no trades. It provides no further details regarding the reasons or …
This article focuses on the cash flow from financing activities for PLUS THERAPEUTICS, Inc. (CNSY) as displayed on TradingView. It provides a financial overview of the company, indicating that the market is currently closed with no trades. The content primarily highlights financial data and …
This article provides the total common shares outstanding for PLUS THERAPEUTICS, Inc. (CNSY) within the TradingView platform. It details the company's financials and offers various market data tools and community features available on TradingView. The content is primarily a data point surrounded by the …
This article provides the price to sales ratio for PLUS THERAPEUTICS, Inc. (CNSY) on the Blue Ocean Alternative Trade System (BOATS). It appears to be a stub or a data point, as the market is closed and no trades are recorded. The content primarily …
This article provides financial information for PLUS THERAPEUTICS, Inc. (NASDAQ: CNSY), a clinical-stage pharmaceutical company focused on rare cancer treatments. It details the company's profile, including its mission, founding, and leadership, but notes a lack of available market capitalization, revenue, and net income data. …
Plus Therapeutics is rebranding to Cerenome, effective August 3, 2026, and will trade under the new Nasdaq ticker CNSY. This strategic shift transforms the company from a therapeutics-focused entity into an integrated CNS oncology company, combining precision diagnostics, targeted therapeutics, and AI to improve …
Plus Therapeutics will rebrand to Cerenome and begin trading on the Nasdaq Capital Market under the ticker symbol CNSY starting August 3, 2026. This change will not affect the company's stock listing status or shareholders' ownership interests. The information for this news brief was …
Formerly known as Plus Therapeutics, Cerenome has rebranded to reflect its evolution into an integrated CNS oncology company. The company aims to improve CNS cancer detection, treatment, and understanding by combining precision diagnostics, targeted therapeutics, and artificial intelligence. This strategy includes its CNSide® Diagnostic …
Plus Therapeutics has rebranded as Cerenome, effective August 3, 2026, with its stock trading under the new Nasdaq ticker "CNSY". The company will focus on integrated CNS oncology, combining precision diagnostics (CNSide), targeted therapeutics (REYOBIQ), and an AI-powered data analytics platform. This strategic shift …
This article provides an overview of market sentiment for Plus Therapeutics Inc. (PSTV), including analyst consensus, short interest trends, and recent insider activities. Four analysts have a "Buy" consensus with a significant average price target upside, though opinions on individual price targets vary widely. …
Plus Therapeutics Inc (PSTV) has a risk assessment score of 2.81, ranking 185 out of 384 in the Biotechnology & Medical Research industry. Its beta of 1.41 indicates higher volatility compared to the S&P 500. The article details various risk metrics including maximum drawdown, …
Plus Therapeutics (PSTV) is set to present new research at the 2026 SNO/ASCO CNS Metastases Conference, focusing on their ReSPECT-LM clinical development program and introducing their new brand, Cerenome. The company will also host a symposium on leptomeningeal metastases management and provide updates on …
Plus Therapeutics, Inc. will present two posters and host a sponsored symposium at the 2026 SNO/ASCO CNS Metastases Conference. The presentations will highlight the Company's REYOBIQ™ clinical development program and CNSide® cerebrospinal fluid diagnostic platform, focusing on improving detection, characterization, treatment, and monitoring of …
Plus Therapeutics Inc. (PSTV) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company's lead candidates, REYOBIQ and Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, target conditions like leptomeningeal metastases, glioblastoma, and solid organ cancers. As …
This article provides an overview of Plus Therapeutics Inc (PSTV)'s dividend history and stock split events. It indicates that the company has not distributed any dividends in the past five years. However, it lists several past and upcoming merger-related stock splits with various ratios.
This article provides the quarterly and annual income statements for Plus Therapeutics Inc (PSTV), offering detailed financial data such as total revenue, operating expenses, R&D expenses, and net income over numerous fiscal periods. The data helps users analyze the company's performance and operational efficiency. …
This article details the shareholder structure of Plus Therapeutics Inc (PSTV), listing major shareholders and their respective proportions. It also provides a breakdown of shareholder types, institutional shareholding over time, and recent shareholder activities including changes in holdings by key institutions.
The NASDAQ page for PLUS THERAPEUTICS Inc. (PSTV) shows a live stock price of $3.83, an increase of $0.05 (1.26%). The stock currently has no analyst ratings or earnings information available. The page also features general information about trading and disclaimers about the risks …
The article provides a valuation analysis for Plus Therapeutics Inc (PSTV), noting its current valuation score of 9.94, which ranks 5th in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -1.09, while indicating that P/B, P/S, and P/CF data …
This Yahoo Finance page provides comprehensive financial data for Plus Therapeutics, Inc. (PSTV), including its current stock price, historical performance, key financial metrics, and analyst ratings. The company is a clinical-stage pharmaceutical firm focused on developing treatments for various cancers, with rhenium obisbemeda as …
Plus Therapeutics, through its subsidiary CNSide Diagnostics, LLC, has signed a regional agreement with Medical Mutual to cover its CNSide® Cerebrospinal Fluid Assay for metastatic CNS cancer. This agreement expands the test's coverage to approximately 1.2 million people in Ohio and Kentucky, bringing the …
Plus Therapeutics' subsidiary, CNSide Diagnostics, has secured a regional agreement with Medical Mutual, extending coverage for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration assay to 1.2 million people in Ohio and Kentucky. This expansion brings the total national coverage to approximately 127 million people. …
Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a regional coverage agreement with Medical Mutual, effective July 1, 2026, which expands CNSide® cerebrospinal fluid assay coverage to an additional 1.2 million people in Ohio and Kentucky. This agreement increases the total contracted coverage for …
Plus Therapeutics (NASDAQ: PSTV) has announced a partnership with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing technology into its CNSide cerebrospinal fluid assay platform. This collaboration aims to enhance the CNSide platform by enabling DNA and RNA profiling across hundreds of biomarkers from …
Plus Therapeutics (Nasdaq: PSTV) announced a collaboration with Genomic Testing Cooperative (GTC) to integrate next-generation sequencing into its CNSide cerebrospinal fluid assay platform. This partnership aims to enable comprehensive DNA and RNA profiling of hundreds of biomarkers from a single CSF specimen, aligning CNSide …
Plus Therapeutics and Genomic Testing Cooperative (GTC) have announced a collaboration to integrate GTC's next-generation sequencing technology into Plus Therapeutics' CNSide® cerebrospinal fluid (CSF) assay platform. This partnership aims to provide comprehensive DNA and RNA profiling from a single CSF specimen, aligning with updated …
Search by ticker symbol or company name and select a result to open its chart.